Literature DB >> 9573257

An evolutionarily conserved splice generates a secreted env-Bet fusion protein during human foamy virus infection.

M L Giron1, H de Thé, A Saïb.   

Abstract

Foamy viruses (spumaretroviruses) represent a retroviral genus which exhibits unusual features relating it to pararetroviruses. Previously, we reported the existence of a protein species harboring Env, Bel, and Bet epitopes in human foamy virus (HFV)-infected cells (M. L. Giron, F. Rozain, M. C. Debons-Guillemin, M. Canivet, J. Périès, and R. Emanoil-Ravier, J. Virol. 67:3596-3600, 1993). Here, we identify this protein as a 160-kDa Env-Bet fusion glycoprotein (gp160) translated from an mRNA species harboring a highly conserved splice site which deletes the membrane anchor domain of Env and fuses the env open reading frame with that of bel1/bet. While gp160 and Bet proteins were both secreted into the supernatant, only Bet was taken up by recipient cells. Since Bet plays a key role in the switch from lytic to chronic infection, secretion of Bet and gp160, together with cellular uptake of Bet, could be highly relevant for both immune response and development of HFV infection in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573257      PMCID: PMC110047          DOI: 10.1128/JVI.72.6.4906-4910.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Sequence analysis of the simian foamy virus type 1 genome.

Authors:  J J Kupiec; A Kay; M Hayat; R Ravier; J Périès; F Galibert
Journal:  Gene       Date:  1991-05-30       Impact factor: 3.688

2.  Analysis of splicing patterns of human spumaretrovirus by polymerase chain reaction reveals complex RNA structures.

Authors:  W Muranyi; R M Flügel
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Arg-Gly-Asp: a versatile cell recognition signal.

Authors:  E Ruoslahti; M D Pierschbacher
Journal:  Cell       Date:  1986-02-28       Impact factor: 41.582

Review 4.  Foamy retroviruses. A virus in search of a disease.

Authors:  R A Weiss
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

5.  Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter.

Authors:  M Löchelt; W Muranyi; R M Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 6.  Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif.

Authors:  S E D'Souza; M H Ginsberg; E F Plow
Journal:  Trends Biochem Sci       Date:  1991-07       Impact factor: 13.807

7.  Structure and transcriptional status of bovine syncytial virus in cytopathic infections.

Authors:  R W Renshaw; M A Gonda; J W Casey
Journal:  Gene       Date:  1991-09-15       Impact factor: 3.688

8.  Human foamy virus polypeptides: identification of env and bel gene products.

Authors:  M L Giron; F Rozain; M C Debons-Guillemin; M Canivet; J Peries; R Emanoil-Ravier
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases.

Authors:  M Roivainen; T Hyypiä; L Piirainen; N Kalkkinen; G Stanway; T Hovi
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  The nucleotide sequences of wild-type coxsackievirus A9 strains imply that an RGD motif in VP1 is functionally significant.

Authors:  K H Chang; C Day; J Walker; T Hyypiä; G Stanway
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

View more
  20 in total

1.  Restriction of foamy viruses by APOBEC cytidine deaminases.

Authors:  Frédéric Delebecque; Rodolphe Suspène; Sara Calattini; Nicoletta Casartelli; Ali Saïb; Alain Froment; Simon Wain-Hobson; Antoine Gessain; Jean-Pierre Vartanian; Olivier Schwartz
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 2.  Foamy viruses are unconventional retroviruses.

Authors:  M L Linial
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

3.  Reactivation of a complex retrovirus is controlled by a molecular switch and is inhibited by a viral protein.

Authors:  Christopher D Meiering; Maxine L Linial
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

4.  Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.

Authors:  Michael Mühle; Kerstin Hoffmann; Martin Löchelt; Joachim Denner
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

5.  An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity.

Authors:  T Pietschmann; H Zentgraf; A Rethwilm; D Lindemann
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Characterization of the R572T point mutant of a putative cleavage site in human foamy virus Env.

Authors:  A Bansal; K L Shaw; B H Edwards; P A Goepfert; M J Mulligan
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Intra- and intercellular trafficking of the foamy virus auxiliary bet protein.

Authors:  Charles-Henri Lecellier; Wim Vermeulen; Françoise Bachelerie; Marie-Lou Giron; Ali Saïb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA.

Authors:  P Soussan; F Garreau; H Zylberberg; C Ferray; C Brechot; D Kremsdorf
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

9.  Cell-type-specific regulation of the two foamy virus promoters.

Authors:  C D Meiering; C Rubio; C May; M L Linial
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

10.  Persistent infection with primate foamy virus type 1 increases human immunodeficiency virus type 1 cell binding via a Bet-independent mechanism.

Authors:  Cecile Schiffer; Charles-Henri Lecellier; Abdelkrim Mannioui; Nathalie Felix; Elisabeth Nelson; Jacqueline Lehmann-Che; Marie-Louise Giron; Jean Claude Gluckman; Ali Saib; Bruno Canque
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.